text stringlengths 0 197k |
|---|
* the five sessions of the case management intervention; |
* two evaluation sessions (pre and post-intervention); |
* a final in-depth semi-structured interview (optional). conditions: Psychiatric Disorder conditions: Involuntary Psychiatric Hospitalization studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 36 type: ESTIMATED name: Brief case management inte... |
<|newrecord|> nctId: NCT06320444 id: CRFSJ0297 briefTitle: Non-invasive Spinal, Cortical, and Sensorimotor Biomarkers in Motor Neurone Disease overallStatus: RECRUITING date: 2023-06-15 date: 2024-12-15 date: 2025-07-15 date: 2024-03-20 date: 2024-03-20 name: University of Dublin, Trinity College class: OTHER name: Mot... |
<|newrecord|> nctId: NCT06320431 id: ACT-WHEN-001 briefTitle: ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 acronym: ACT-WHEN overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2030-09-30 date: 2030-12-31 date: 2024-03-20 date: 2024-04-25 name: University ... |
This domain aim is to efficiently, reliably, and simultaneously, determine the comparative effectiveness of intravenous thrombolysis (IVT) using standard-dose intravenous tenecteplase (0.25 mg/kg body weight), vs. low-dose intravenous tenecteplase (0.18 mg/kg body weight) in all patients who present to hospital with ac... |
This domain will currently evaluate four research questions in relation to the use of IVT with tenecteplase: |
1. In patients with recent (24 hours) intake of a standard-dose direct oral anticoagulant (DOAC), how should IVT be used? - Use standard-dose (0.25 mg/kg body weight) or low-dose tenecteplase (0.18 mg/kg) or not at all. |
2. In patients planned to be treated with endovascular thrombectomy, how should tenecteplase be used? -Treat with IV tenecteplase (standard- or low-dose) or not at all. |
3. In any patient receiving IVT, what is the optimal dose of tenecteplase? - use standard-dose (0.25 mg/kg body weight) or low-dose tenecteplase (0.18 mg/kg). |
4. To what extent is the treatment effect of standard- vs. low-dose tenecteplase modified by key patient characteristics, such as diabetes, prior antiplatelet therapy, renal failure, or frailty, old age or having a heavy burden of cerebral small vessel disease on brain imaging. conditions: Acute Ischemic Stroke AIS con... |
This will result in four pre-defined strata: (i) EVT+ / DOAC+ (ii) EVT+ / DOAC- (iii) EVT- / DOAC+ and (iv) EVT- / DOAC-. |
Patients in strata 1, 2 and 3 will be randomized to standard-dose IV tenecteplase (0.25 mg/kg body weight) vs. Low-dose tenecteplase (0.18 mg/kg body weight) or no IV thrombolysis (1:1:1 randomization). Patients in strata 4 will be randomized to standard-dose intravenous (IV) tenecteplase (0.25 mg/kg body weight) vs. L... |
Emergency EVT is defined as anticipated arterial puncture time in the enrolling hospital ≤ 60 minutes from randomization. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The trial will have allocation concealment and blinded endpoint assessment, but open-label treatment. Given the time sensitive nature of... |
The trial will have blinded endpoint assessment on Day 90, with central blinded assessors contacting the participants. whoMasked: OUTCOMES_ASSESSOR count: 4000 type: ESTIMATED name: Tenecteplase measure: A reduction of functional dependence analyzed across the whole distribution of outcomes assessed on the modified Ran... |
<|newrecord|> nctId: NCT06320418 id: RHDIRB2020110301REC#196 briefTitle: The Epigenetic Regulatory Role of P-element Induced Wimpy Testis (Piwi) Interacting RNA-823 (piR-823) in Ovarian Cancer Progression overallStatus: ACTIVE_NOT_RECRUITING date: 2022-06-15 date: 2023-12-10 date: 2024-06 date: 2024-03-20 date: 2024-03... |
<|newrecord|> nctId: NCT06320405 id: STUDY00025940 id: NCI-2024-01397 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: STUDY00025940 type: OTHER domain: OHSU Knight Cancer Institute briefTitle: Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Me... |
<|newrecord|> nctId: NCT06320392 id: RHDIRB2020110301 REC#48 briefTitle: Implication of CCR4-NOT Complex Subunit 7 Expression in Natural Killer Cell Resistance in Metastatic Breast Cancer acronym: CCR4-NOT overallStatus: ACTIVE_NOT_RECRUITING date: 2021-07-01 date: 2023-05-01 date: 2024-06-01 date: 2024-03-20 date: 202... |
<|newrecord|> nctId: NCT06320379 id: RB071522 briefTitle: Zypan Functional Dyspepsia overallStatus: RECRUITING date: 2023-03-15 date: 2024-06-01 date: 2024-12-31 date: 2024-03-20 date: 2024-03-20 name: National University of Natural Medicine class: OTHER briefSummary: The purpose of this study is to determine the effec... |
<|newrecord|> nctId: NCT06320366 id: 23-1044 id: K24DA058882 type: NIH link: https://reporter.nih.gov/quickSearch/K24DA058882 briefTitle: Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2028-05-31 date: 2028-05-31 date: 2024-03-20 date: 2024-... |
<|newrecord|> nctId: NCT06320353 id: CL01860211 briefTitle: Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma overallStatus: ACTIVE_NOT_RECRUITING date: 2023-09-27 date: 2024-06 date: 2026-01 date: 2024-03-20 date: 2024-03-20 name: R-Pharm class: ... |
The main task is to evaluate and compare the effectiveness of RPH-075 and Keytruda® drugs when used in patients with unresectable or metastatic skin melanoma as a 1 or 2 line therapy in monotherapy regimen, according to the objective response rate (ORR) parameter for up to 24 weeks of therapy. conditions: Skin Melanoma... |
<|newrecord|> nctId: NCT06320340 id: 07032024 briefTitle: Effectiveness of NMES on Neck Pain overallStatus: COMPLETED date: 2021-03-15 date: 2021-05-15 date: 2021-09-15 date: 2024-03-20 date: 2024-03-20 name: Istanbul University - Cerrahpasa (IUC) class: OTHER briefSummary: The aim of this randomized-controlled study w... |
<|newrecord|> nctId: NCT06320327 id: 80177 briefTitle: Topical CBD's Effects on Soreness and Performance overallStatus: COMPLETED date: 2022-08-23 date: 2023-04-27 date: 2023-04-30 date: 2024-03-20 date: 2024-03-20 name: Joseph Pastina class: OTHER briefSummary: Exercise-induced muscle damage (EIMD) results from unaccu... |
Therefore, the purpose of the present study was to investigate the effects of CBD cream on DOMS and performance after an intensive lower-body exercise protocol. Specifically, the study's aims were: |
Aim 1: To assess the effect of topical CBD cream administration on muscle soreness following fatiguing exercise. |
Hypothesis 1: CBD cream would decrease perceived muscle soreness when compared to a placebo or control (no cream) group. |
Aim 2: To assess the effect of topical CBD cream administration on muscular performance following fatiguing exercise. |
Hypothesis 2: Recovery of muscular power would be quicker when CBD cream is applied, compared to a placebo or control (no cream) group. |
Aim 3: To assess if topical CBD cream has a localized (if any) or systemic effect on muscle soreness. |
Hypothesis 3: Improvements in muscle soreness would only be observed in localized muscles around where the CBD cream was applied. conditions: Muscle Soreness studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE maskingDescription: The re... |
<|newrecord|> nctId: NCT06320314 id: LRP23021-E serum briefTitle: Efficacy and Tolerability of Tested Formula After 3 Months in Treatment of Facial Hyperpigmentation of 3 Origins overallStatus: RECRUITING date: 2024-02-19 date: 2024-05-22 date: 2024-05-22 date: 2024-03-20 date: 2024-03-20 name: Cosmetique Active Intern... |
<|newrecord|> nctId: NCT06320301 id: SYSKY-2024-027-01 briefTitle: Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC) overallStatus: RECRUITING date: 2024-04-01 date: 2026-02-01 date: 2026-06-01 date: 2024-03-20 date: 2024-03-20 name: Sun Yat-Sen Memorial Hos... |
<|newrecord|> nctId: NCT06320288 id: IRR-FLAVIGNY-2023-1 briefTitle: Analysis of Trunk and Center of Mass Control Development During Gait in Children With Cerebral Palsy (VERTEBRAL) acronym: VERTEBRAL overallStatus: RECRUITING date: 2023-09-20 date: 2025-09 date: 2028-09 date: 2024-03-20 date: 2024-03-20 name: Union de... |
<|newrecord|> nctId: NCT06320275 id: self-efficiency briefTitle: Fathers' Breastfeeding Self-efficiency overallStatus: COMPLETED date: 2023-02-01 date: 2023-05-30 date: 2023-07-30 date: 2024-03-20 date: 2024-03-20 name: Cukurova University class: OTHER briefSummary: The purpose of this study was planned to examine the ... |
<|newrecord|> nctId: NCT06320262 id: NRC/TDF/01/F briefTitle: Evaluation of the Effect of Wet Cupping (Hijama) on Primary Fibromyalgia overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-10 date: 2025-04 date: 2024-03-20 date: 2024-03-22 name: Rasmia Elgohary class: OTHER briefSummary: Fibromyalgia has become on... |
This study aims to investigate the effectiveness of wet cupping therapy combined with home-based exercise compared to home-based exercise alone in improving patients diagnosed with primary fibromyalgia syndrome. conditions: Treatment studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLE... |
<|newrecord|> nctId: NCT06320249 id: WJYY-XZKT-2023-05 briefTitle: Rotation-traction Manipulation of Different Treatment Frequency in Cervical Radiculopathy overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-04-30 date: 2025-06-30 date: 2024-03-20 date: 2024-03-20 name: Wangjing Hospital, China Academy of Ch... |
<|newrecord|> nctId: NCT06320236 id: 4603 briefTitle: Emergency Medicine Pulmonary Embolism Testing Multicentre Study acronym: EMPET overallStatus: RECRUITING date: 2024-01-01 date: 2026-09-30 date: 2027-09-30 date: 2024-03-20 date: 2024-03-20 name: Dr. Kerstin de Wit class: OTHER name: Canadian Institutes of Health Re... |
We have created a new tool (called Adjust-Unlikely) which could safely reduce pulmonary embolism imaging in Canada. Our research group composed of researchers, emergency physicians, and patients developed the Adjust-Unlikely clinical decision rule: a rule which has been customized for emergency physicians and emergency... |
Our study aim is to prospectively validate Adjust-Unlikely pulmonary embolism testing in emergency patients with suspected pulmonary embolism. conditions: Pulmonary Embolism conditions: D-dimer conditions: Diagnosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 4000 type: ESTIM... |
<|newrecord|> nctId: NCT06320223 id: PROMISE PET Registry briefTitle: PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer acronym: PROMISE-PET overallStatus: RECRUITING date: 2024-03-05 date: 2034-03-05 date: 2035-03-05 date: 2024-03-20 date: 2024-03-20 name: University Hospital, Essen class: OTHER briefSum... |
PROMISE criteria have been defined for standardized reporting of Prostate-Specific Membrane Antigen (PSMA) PET whole-body stage of prostate cancer. PSMA PET disease extent by PROMISE has been associated with oncologic outcome. |
Need: |
Improved prognostication across various stages of prostate cancer is needed for management guidance and study design. |
Aim: |
1. To assess the prognostic value of PSMA PET |
2. To compare the prognostic value of PSMA PET with clinical prognostic scores in patients with prostate cancer at various disease stages |
Inclusion: |
* Adult patients with |
* biopsy/histo proven prostate cancer who |
* underwent PSMA PET (any type) |
* for staging or re-staging at any stage and who |
* have at least 3-year overall survival follow-up data available will be included consecutively. |
Exclusion: |
* Patients with neuroendocrine prostate cancer |
* Patients with metastasized or disseminated malignancy other than prostate cancer conditions: Prostate Cancer conditions: PET/CT conditions: Survivorship conditions: PSMA studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 10000 type: ESTIMATED measure: Overall survival measure: Met... |
<|newrecord|> nctId: NCT06320210 id: IRB19-1308 briefTitle: Chicago Asthma School-Directed Child-Centered Assessment and Dissemination of Evidence acronym: CASCADE overallStatus: RECRUITING date: 2023-08-31 date: 2025-08-31 date: 2025-12-30 date: 2024-03-20 date: 2024-04-11 name: University of Chicago class: OTHER brie... |
<|newrecord|> nctId: NCT06320197 id: DROWN_INSITU briefTitle: In Situ Simulation Training in Lifeguard Organisations acronym: DROWN_INSITU overallStatus: RECRUITING date: 2018-01-01 date: 2024-12-31 date: 2024-12-31 date: 2024-03-20 date: 2024-03-20 name: Prehospital Center, Region Zealand class: OTHER briefSummary: Th... |
<|newrecord|> nctId: NCT06320184 id: INT 0083/23 briefTitle: AI for Lung Cancer Risk Definition in Computed Tomography Screening Programs overallStatus: ACTIVE_NOT_RECRUITING date: 2023-04-30 date: 2024-10-30 date: 2026-04-30 date: 2024-03-20 date: 2024-03-22 name: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano... |
In this respect, the investigators already demonstrated that the combination of baseline LDCT features with a minimal invasive microRNA blood test was able to more precisely estimate the individual risk of developing LC. The investigators posit that additional immune-related and radiologic features can be integrated wi... |
<|newrecord|> nctId: NCT06320171 id: 240118,2024-481 briefTitle: Efectivity of Non-invasive Neuromodulation in Parasympathic Nervous System and Vascular System overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-04 date: 2024-06 date: 2024-03-20 date: 2024-03-20 name: Universidad Europea de Madrid class: OTHER b... |
<|newrecord|> nctId: NCT06320158 id: PNRR-MAD-2022-12376672 briefTitle: Dissecting the Molecular and Cellular Pathophysiology of Sarcopenic Obesity in the Elderly overallStatus: RECRUITING date: 2023-05-22 date: 2024-10-31 date: 2024-12-31 date: 2024-03-20 date: 2024-03-28 name: IRCCS San Raffaele class: OTHER briefSum... |
The study design designed to achieve this aim is a cross-sectional observational study with an additional multicentre procedure lasting two years. conditions: Sarcopenic Obesity studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1108 type: ESTIMATED name: clinical evaluation of sarc... |
<|newrecord|> nctId: NCT06320145 id: P.T.REC/012/004045 briefTitle: Effect of Cryotherapy on Primary Dysmenorrhoea overallStatus: COMPLETED date: 2023-03-13 date: 2023-09-13 date: 2023-10-01 date: 2024-03-20 date: 2024-03-20 name: Cairo University class: OTHER briefSummary: Dysmenorrhea is a menstrual disorder defined ... |
Cryotherapy, therapeutic cooling, is one of the modalities widely used in sports medicine for a variety of treatment purposes. Physiological and neurological responses of musculoskeletal tissues to cooling have been extensively examined in the literature. conditions: Dysmenorrhea Primary studyType: INTERVENTIONAL phase... |
<|newrecord|> nctId: NCT06320132 id: BLANDISH briefTitle: BLANDISH (Brain, Loss of Function, Aneurism, Disease, Injury, Stroke, Hemorrhage) acronym: BLANDISH overallStatus: RECRUITING date: 2024-03-13 date: 2028-12-31 date: 2029-01-31 date: 2024-03-20 date: 2024-03-20 name: IRCCS Ospedale San Raffaele class: OTHER brie... |
Participants will be treated as per standard clinical practice. conditions: Intracranial Hemorrhages studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 2000 type: ESTIMATED name: Treatment of spontaneous intracranial hemorrhage measure: Mortality sex: ALL minimumAge: 18 Years st... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.